ADC Therapeutics SA has entered a R&D pact with Affimer developer Avacta Group plc aimed at creating and licencing Affimer drug conjugates.
Under the terms of the agreement, Avacta Group (Cambridge, UK) will provide three small Affimer proteins designed to bind to undisclosed cancer targets with similar specificity and affinity to that of antibodies. ADC Therapeutics SA (Lausanne, Switzerland) will utilise its pyrrolobenzodiazepine (PBD)-based warhead and linker technologies to create Affimer drug conjugates. Furthermore, ADC Therapeutics will evaluate each of the Affimer drug conjugates (Affi-DC) preclinically.